These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15586138)

  • 21. Unique roles of a data and safety monitoring board in vaccine safety trials with compressed timelines and urgent implications.
    Scheifele D; Duval B; De Serres G; Skowronski DM
    Control Clin Trials; 2003 Feb; 24(1):99-104. PubMed ID: 12559648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [DSMB. 2. The importance of an efficient DSMB: some examples of high-risk clinical trials].
    Brun-Buisson C
    Med Sci (Paris); 2005 Feb; 21(2):187-9. PubMed ID: 15691491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Independent data and safety monitoring in psychiatric intervention research.
    Leon AC
    J Clin Psychiatry; 2012 Feb; 73(2):e257-63. PubMed ID: 22401486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The conscientious judgement of a DSMB--statistical stopping rules re-examined.
    Hedenmalm K; Melander H; Alvan G
    Eur J Clin Pharmacol; 2008 Jan; 64(1):69-72. PubMed ID: 18000658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survey of professional views on sharing interim results by the Data Safety Monitoring Board (DSMB): what to share, with whom and why.
    Borg Debono V; Mbuagbaw L; Paul J; Buckley N; Thabane L
    Trials; 2018 May; 19(1):281. PubMed ID: 29784030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What information should a sponsor of a randomized trial receive during its conduct?
    Anand SS; Wittes J; Yusuf S
    Clin Trials; 2011 Dec; 8(6):716-9. PubMed ID: 22024103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Guidelines for Data and Safety Monitoring in Pragmatic Randomized Clinical Trials Using Case Studies.
    Zahrieh D; Croghan IT; Inselman JW; Mandrekar SJ
    Mayo Clin Proc; 2023 Nov; 98(11):1712-1726. PubMed ID: 37923529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Data monitoring committees for pragmatic clinical trials.
    Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
    Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial.
    Cairns JA; Wittes J; Wyse DG; Pogue J; Gent M; Hirsh J; Marler J; Pritchett EL
    Am Heart J; 2008 Jan; 155(1):33-41. PubMed ID: 18082486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developing training for Data Safety Monitoring Board members: A National Institute of Allergy and Infectious Diseases case study.
    Zuckerman J; van der Schalie B; Cahill K
    Clin Trials; 2015 Dec; 12(6):688-91. PubMed ID: 26152835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Data and Safety Monitoring Board Monitoring of Clinical Trials for Early Efficacy.
    Dodd LE; Proschan MA
    NEJM Evid; 2022 Mar; 1(3):EVIDctw2100025. PubMed ID: 38319232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Forming your phase III trial's data and safety monitoring board: a perspective on safety.
    Wittes J
    J Investig Med; 2004 Nov; 52(7):453-8. PubMed ID: 15651261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The other side of clinical trial monitoring; assuring data quality and procedural adherence.
    Williams GW
    Clin Trials; 2006; 3(6):530-7. PubMed ID: 17170037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Monitoring the safety of participants in randomised clinical trials: basis and methods].
    Tijssen JG
    Ned Tijdschr Geneeskd; 2008 Mar; 152(12):674-8. PubMed ID: 18438062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know.
    Neaton JD; Grund B; Wentworth D
    Clin Trials; 2018 Aug; 15(4):359-365. PubMed ID: 29552920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Data monitoring committees, interim analysis and early termination in paediatric trials.
    Fernandes RM; van der Lee JH; Offringa M
    Acta Paediatr; 2011 Oct; 100(10):1386-92. PubMed ID: 21434998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Data monitoring in randomized controlled trials: surveys of recent practice and policies.
    Clemens F; Elbourne D; Darbyshire J; Pocock S;
    Clin Trials; 2005; 2(1):22-33. PubMed ID: 16279576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The agonising negative trend in monitoring of clinical trials.
    DeMets DL; Pocock SJ; Julian DG
    Lancet; 1999 Dec; 354(9194):1983-8. PubMed ID: 10622312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.